tarcocimab tedromer - Business-News-Today.com

🧬 Interested in pharma, biotech and medical device news? Visit PharmaDeviceNews.com →

Business news, market intelligence, and global industry analysis.

The Latest

Mesoblast (ASX: MSB) clears key treatment milestone ahead of mid-2027 back pain trial readout

Santos (ASX: STO) warns Australia’s 20% gas reservation rule could undermine GLNG economics

Russian missiles strike Kyiv as attacks injure 17 in Zaporizhzhia and Kharkiv

Regis Resources (ASX: RRL) drops Vault Minerals bid, letting Genesis Minerals’s A$5.6bn offer proceed

Kodiak Sciences advances Phase 3 GLOW2 study for diabetic retinopathy, evaluating tarcocimab tedromer with extended dosing intervals, aiming for significant patient outcomes.

Read More

Pharma Industry News

Kodiak Sciences advances Phase 3 study of tarcocimab tedromer in diabetic retinopathy

Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company focused on developing transformative therapeutics for retinal diseases, announced that…

byPallavi Madhiraju

May 14, 2024

web analytics